0 Kommentare
0 Geteilt
2KB Ansichten
0 Bewertungen
Suche
Entdecken Sie neue Leute, knüpfen Sie neue Kontakte und schließen Sie neue Freundschaften
-
Newsfeed
- ERKUNDEN
-
Seiten
-
Gruppen
-
Veranstaltungen
-
Reels
-
Blogs
-
Marktplatz
-
Angebote
-
Jobs
-
Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!
-
Stem Cell Therapy Market Growth: Biotechnology Innovations Reshaping HealthcareIn an increasingly competitive and evolving business landscape, making informed decisions backed by reliable data has become essential for sustained growth and strategic planning. Market intelligence serves as a critical tool for businesses to respond effectively to shifting consumer demands, technological advancements, and emerging market trends. At Polaris Market Research, we are committed to...0 Kommentare 0 Geteilt 2KB Ansichten 0 Bewertungen
-
Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in EuropeAlvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...0 Kommentare 0 Geteilt 208 Ansichten 0 Bewertungen
-
Cell Therapy Instrument Market Future Scope in Personalized Medicine SolutionsThe global cell therapy instrument market is witnessing substantial growth due to the increasing demand for advanced regenerative medicine, rising investments in biotechnology research, and expanding applications of cell-based therapies in disease treatment. Cell therapy instruments play a critical role in the development, processing, monitoring, and manufacturing of cell therapies used in...0 Kommentare 0 Geteilt 2KB Ansichten 0 Bewertungen
-
Danaher (DHR) raised its 2026 profit outlook as core sales grew only 3.0%Adjusted earnings per share rose 11.5% in the third quarter while core sales grew 3.0%, and the full-year range moved up by less than the quarter's gain. Cash flow and segment mix tell a narrower story. Danaher Corporation (DHR) reported third-quarter 2026 results on October 21 and raised its full-year adjusted earnings guidance. Adjusted diluted earnings per share reached $2.11, up from $1.89...0 Kommentare 0 Geteilt 52 Ansichten 0 Bewertungen
-
Global Biomarkers Market to Surge to USD 267.23 Billion by 2033, Driven by Advances in Precision MedicineThe global biomarkers market size was valued at USD 89.81 billion in 2024 and is expected to grow from USD 101.38 billion in 2025 to reach USD 267.23 billion in 2033, growing at a CAGR of 12.88% during the forecast period (2025–2033). How Is the Biomarkers Market Analyzed and What Research Methodology Is Used? The study examines the Biomarkers...0 Kommentare 0 Geteilt 3KB Ansichten 0 Bewertungen
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Kommentare 0 Geteilt 104 Ansichten 0 Bewertungen
-
Sports Medicine Biologics Market: Advances in Orthopedic Injury ManagementSports Medicine Biologics Market: Growth, Trends, and Forecast to 2034 Overview The global Sports Medicine Biologics Market was valued at USD 2.04 billion in 2026 and is projected to reach USD 3.09 billion by 2034, expanding at a CAGR of 5.6% during the forecast period. Market growth is supported by rising sports-related injuries, increasing participation in physical activities, and growing...0 Kommentare 0 Geteilt 10 Ansichten 0 Bewertungen
-
US Human Rabies Immunoglobulin Market Trends, Competitive Analysis and Future OpportunitiesThe United States represents a significant market for human rabies immunoglobulin due to its well-established healthcare infrastructure, widespread availability of post-exposure prophylaxis treatments, and strong public health surveillance systems. Although human rabies cases remain relatively rare in the country, healthcare providers maintain strict protocols for managing potential rabies...0 Kommentare 0 Geteilt 1KB Ansichten 0 Bewertungen
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek